Analysts Set Expectations for Immunovant FY2027 Earnings

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2027 earnings per share estimates for Immunovant in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($3.26) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share.

A number of other research firms have also weighed in on IMVT. UBS Group reiterated a "neutral" rating and issued a $17.00 price objective (down previously from $38.00) on shares of Immunovant in a research note on Tuesday, April 22nd. Guggenheim reaffirmed a "buy" rating on shares of Immunovant in a report on Thursday, March 20th. Bank of America reduced their price objective on Immunovant from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Jefferies Financial Group assumed coverage on Immunovant in a report on Monday, March 3rd. They issued a "hold" rating and a $20.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $51.00 target price on shares of Immunovant in a report on Wednesday, March 19th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.33.

Immunovant Price Performance

IMVT traded down $0.28 during trading on Tuesday, reaching $15.66. 1,085,179 shares of the company's stock were exchanged, compared to its average volume of 1,213,526. Immunovant has a 1 year low of $12.72 and a 1 year high of $34.47. The company's fifty day simple moving average is $14.95 and its 200-day simple moving average is $19.75. The stock has a market capitalization of $2.68 billion, a P/E ratio of -5.98 and a beta of 0.61.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Thursday, May 29th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.08. The firm had revenue of $0.16 million during the quarter. During the same quarter in the prior year, the company posted ($0.52) EPS.

Insiders Place Their Bets

In related news, CEO Peter Salzmann sold 28,094 shares of Immunovant stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $12.99, for a total value of $364,941.06. Following the completion of the transaction, the chief executive officer now owns 1,186,512 shares in the company, valued at $15,412,790.88. The trade was a 2.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eva Renee Barnett sold 2,993 shares of the company's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $14.89, for a total value of $44,565.77. Following the completion of the transaction, the chief financial officer now directly owns 396,774 shares of the company's stock, valued at $5,907,964.86. The trade was a 0.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,682 shares of company stock worth $596,619. Company insiders own 5.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IMVT. Strs Ohio acquired a new stake in Immunovant in the 1st quarter valued at $27,000. FNY Investment Advisers LLC purchased a new position in Immunovant during the first quarter valued at $34,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Immunovant in the first quarter valued at about $37,000. Headlands Technologies LLC purchased a new stake in shares of Immunovant during the first quarter worth about $51,000. Finally, Covestor Ltd increased its stake in shares of Immunovant by 187.5% during the first quarter. Covestor Ltd now owns 3,764 shares of the company's stock worth $64,000 after purchasing an additional 2,455 shares in the last quarter. 47.08% of the stock is owned by institutional investors and hedge funds.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.